[HTML][HTML] Sirolimus conversion for patients with posttransplant Kaposi's sarcoma
C Lebbe, S Euvrard, B Barrou, C Pouteil-Noble… - American Journal of …, 2006 - Elsevier
This retrospective study aimed to evaluate the benefit of switching from calcineurin inhibitors
(CnI) to sirolimus in posttransplant Kaposi's sarcoma (KS). Fourteen patients monitored in
five French departments who had developed posttransplant KS were switched from CnI to
sirolimus either abruptly (n= 9) or progressively (n= 5) with trough levels 5–12 ng/mL. Two
patients had a complete remission, eight a partial response, and five no significant
improvement of KS. The mean time to response was 3.9 months. After a mean follow-up of …
(CnI) to sirolimus in posttransplant Kaposi's sarcoma (KS). Fourteen patients monitored in
five French departments who had developed posttransplant KS were switched from CnI to
sirolimus either abruptly (n= 9) or progressively (n= 5) with trough levels 5–12 ng/mL. Two
patients had a complete remission, eight a partial response, and five no significant
improvement of KS. The mean time to response was 3.9 months. After a mean follow-up of …